Barclays backs Dormakaba with CHF880 target on U.S. growth, margin gains

Barclays has initiated "overweight" coverage on Dormakaba Holding AG with an CHF880 price target, implying a 23.1% upside, citing the Swiss access solutions company as a "classic self-help story" poised for significant margin expansion. The brokerage projects Dormakaba's EBITDA margins to rise from 14.7% in 2024 to 17.9% by 2027, driven by over CHF220 million in targeted structural savings aimed at closing its profitability gap with peers. Despite currently trading at a 10-15% valuation discount to rivals, Barclays views this as unwarranted given the company's robust strategic focus, particularly in the U.S., and ample balance sheet optionality for M&A, suggesting a much-improved franchise quality post-transformation.

Analysis

Barclays has initiated coverage on Dormakaba Holding AG with an "overweight" rating and a CHF880 price target, implying a 23.1% upside based on the thesis of a "classic self-help story" with significant margin expansion potential that is not fully priced in by the market. Dormakaba, a top-three player in the global access solutions market, currently lags peers like Assa Abloy and Allegion on profitability, with selling, general, and administrative costs running 400 to 600 basis points higher. The core of the bull case rests on management's plan to deliver over CHF220 million in structural savings by fiscal 2027/28, which is projected to add 250 basis points to adjusted EBIT margins. Barclays' forecasts reflect this, projecting adjusted EBITDA margins to expand from 14.7% in 2024 to 17.9% by 2027. Further supporting the outlook is the company's underleveraged balance sheet, with a net debt-to-EBITDA ratio of approximately 1x, providing substantial capacity for acquisitions—a growth lever the company has historically underutilized compared to peers. This financial flexibility, combined with a strategic priority to grow U.S. sales from CHF722 million to over CHF1 billion by 2028, provides a clear path to growth. Despite this potential, Dormakaba currently trades at a 10-15% valuation discount to its peer group, which Barclays suggests is unwarranted and likely to close as the company executes its transformation.

Key Decisions for Investors

• Investors should consider the stock as a potential value and growth play, contingent on management's successful execution of its margin expansion program, which could trigger a significant valuation re-rating.
• Monitor key performance indicators related to the company's structural savings plan, specifically progress towards the CHF220 million target and the subsequent improvement in adjusted EBIT and EBITDA margins versus peers.
• Watch for any M&A activity, particularly in the strategic U.S. market, as the company's strong balance sheet provides a catalyst for accretive acquisitions that could accelerate growth beyond internal efforts.
• Given the stock trades at a 10-15% discount to peers, the current price may represent an attractive entry point for those confident in the 'self-help' narrative, but this is dependent on quarterly results confirming the margin improvement trajectory.